Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1

Interventions

Cisplatin 136Radiotherapy 90Cetuximab 89pembrolizumab 65Fluorouracil 56Docetaxel 56Carboplatin 51Paclitaxel 44Radiotherapy, Intensity-Modulated 37Nivolumab 35durvalumab 19Erlotinib Hydrochloride 18Immunohistochemistry 16Radiation 13tremelimumab 12Gemcitabine 11Surgical Procedures, Operative 10Gene Expression Profiling 10Drug Therapy 10Biopsy 10Albumin-Bound Paclitaxel 10Chemotherapy, Adjuvant 9Capecitabine 9Bevacizumab 9atezolizumab 8Radiosurgery 8Polymerase Chain Reaction 8Neoadjuvant Therapy 8Ipilimumab 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Squamous Cell Carcinoma of Head and Neck × Toll-Like Receptor 1 × Clear all
NCT03083873 2023-10-12

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Iovance Biotherapeutics, Inc.

Phase 2 Completed
64 enrolled 15 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡